Trial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now.
3P Biopharmaceuticals has hired Andrew Carver as its new Senior Head of Business Development. Carver joins 3P from UK-based CDMO Fujifilm Diosynth Biotechnology.
After being leaderless for over a year, EffRx has a new CEO. In October, EffRx announced that Lorenzo Bosisio has taken over the companys helm in July.
New name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-10-20 11:21:042016-10-20 11:21:04Dilaforette: Going public with a new name
Spanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, medtech and diagnostics companies.
Swiss oncology expert Nouscom has appointed Marina Udier Blagovic as its Chief Operating Officer. The position has been newly created to drive all aspects of business operations and business development.
https://european-biotechnology.com/wp-content/uploads/2024/04/marina-udier-blagovic.jpg430382h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-19 07:09:002016-10-19 07:09:00Nouscom: New hire for operations
Cambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs.
https://european-biotechnology.com/wp-content/uploads/2024/04/Drooms_Whitepaper.png360640Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2016-10-17 16:12:172016-10-17 16:12:1714 Must-Haves to Boost the Efficiency of Your Data Room
Apitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will take over commercialisation cost following Phase II testing. Phase II data are due to be published in Q4/2016.
https://european-biotechnology.com/wp-content/uploads/2024/04/news_domain_model_tag_add.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-10-17 10:23:592016-10-17 10:23:59Merck drops MS collaboration with Apitope
Oslo-based Nordic Nanovector has elected Joanna Horobin to its board as Non-executive Board Director. She replaces Renee Tannenbaum who stepped down from the board for personal reasons.
https://european-biotechnology.com/wp-content/uploads/2024/04/joanna-horobin.jpg286254h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-17 07:21:002016-10-17 07:21:00Nordic Nanovector: New on board
EMA unveils trial data
Latest News3P Biopharmaceuticals: Business Developer
AppointmentsEffRx Pharmaceuticals: Filling a vacancy
AppointmentsDilaforette: Going public with a new name
Latest NewsNew name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.
Ysios closes €126m BioFund
Latest NewsSpanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, medtech and diagnostics companies.
Nouscom: New hire for operations
AppointmentsCrescendo Biologics: Finance pro
AppointmentsCambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs.
14 Must-Haves to Boost the Efficiency of Your Data Room
Sponsored PublicationsStop wasting time with data room software that doesnt really improve your workflow.
Merck drops MS collaboration with Apitope
Latest NewsApitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will take over commercialisation cost following Phase II testing. Phase II data are due to be published in Q4/2016.
Nordic Nanovector: New on board
Appointments